Compugen Ltd.

NASDAQ:CGEN

Biotechnology

Healthcare
$2.02 +0.50%

+$0.01 today

Market cap
$191.34M
Beta
2.74
P/E (TTM)
5.4
EPS (TTM)
$0.37
52W Low $1.30High $3.24

Volume 0.20M

Average 0.48M

CGEN Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Compugen Ltd.NASDAQ: CGEN

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $9.37M rose 13.2% year over year, ahead of the -2.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 20.8% from the prior quarter. Over 3 fiscal years it compounded at -8.4% a year.

Context

  • Operating expenses amounted to 44.2% of revenue in FY2025, down 80.7 pp from a year earlier.
  • Operating expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +13.2% holds above the trailing-twelve-month pace of -2.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.37M+20.8% QoQ
Last fiscal yearDec 2025
$32.19M-7.6% YoY
LTMMar 2026
$33.28M-2.6% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.2%——
1 year-7.6%——
3-year CAGR-8.4%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
32.19M USD
Year-over-year change
-7.6%
4-year CAGR
-5.5%

Operating Expenses vs competitors

How CGEN compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2.6% is the 6th highest of 9, against a peer median of +31.6%.
  • Operating expenses amounts to 45.8% of revenue for CGEN, versus a peer median of 2016.9%.
CGEN Competitors
Operating Expenses for CGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$160.42M USD+112.7%+5.1%913.8%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$89.69M USD+109.1%+36.8%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$67.15M USD+28.8%-0.4%3764.1%
MOLNMolecular Partners AGLTM Mar 2026CHF 63.08M CHF+100.0%-11.3%—
IPHAInnate Pharma S.A.FY2025€56.21M EUR-12.4%-3.9%2016.9%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$37.64M USD-28.3%-14.9%1187.9%
CRDFCardiff Oncology, Inc.LTM Mar 2026$36.37M USD-15.3%+7.1%6928.2%
CGENCompugen Ltd.LTM Mar 2026$33.28M USD-2.6%-8.4%45.8%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$28.27M USD+34.5%+12.8%—
Peer median (excluding CGEN) —+31.6%+2.4%2016.9%

Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6M7.5M33.46M27.86M72.76M
Cost of Revenue680K975K2M7.93M9.25M
Gross Profit5.32M6.53M31.46M19.93M63.51M
Gross Margin88.7%87.0%94.0%71.5%87.3%
Research & Development28.69M30.65M34.47M24.81M22.76M
Selling, General & Admin11.7M11.25M9.98M10.02M9.43M
Operating Expenses40.39M41.9M44.45M34.83M32.19M
Depreciation & Amortization461K482K476K486K475K
EBITDA(33.72M)(33.13M)(9.28M)(9.19M)35.87M
EBITDA Margin-562.0%-441.7%-27.7%-33.0%49.3%
Operating Income(35.07M)(35.37M)(12.99M)(14.89M)31.33M
Operating Margin-584.6%-471.7%-38.8%-53.4%43.1%
Interest Income894K1.44M3.24M5.24M4.41M
Interest Expense25K27K31K34K0
Other Income / Expenses871K1.74M3.21M5.18M4.07M
Income Before Tax(34.2M)(33.64M)(9.78M)(9.71M)35.4M
Pre-Tax Margin-570.0%-448.5%-29.2%-34.8%48.6%
Income Tax Expense058K8.97M4.52M54K
Net Income(34.2M)(33.69M)(18.75M)(14.23M)35.34M
Net Margin-570.0%-449.3%-56.1%-51.1%48.6%
EPS (Basic)(0.41)(0.39)(0.21)(0.16)0.38
EPS (Diluted)(0.41)(0.39)(0.21)(0.16)0.38
Weighted Avg Shares84.2M86.56M87.63M89.53M93.43M
Weighted Avg Shares (Diluted)84.2M86.56M87.63M89.53M93.82M

Compugen Ltd.

NASDAQ:CGEN

Intrinsic Alpha fair value

Locked

Current Price

$2.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.